T2DM patients with CVD on sodium glucose co-transporter 2 inhibitor (SGLT-2i) have shown reduction in cardiovascular death and hospitalization for heart failure (HHF).
This study used clinical practice data from 2012-2016 and compared HHF and death in patient with/without prior CVD or heart failure in new users of SGLT-2i vs other glucose lowering drugs (oGLD).
HHF and deaths were collected via medical records, medical claims, electronic health and death records, and national register; Hazard ratio (HR) for HHF, death and the composite endpoint (HHF or death) was calculated as average.
Overall, 306,156 patients with >150,000 person year(PY) 100,947 PY for SGLT-2i; 89,208 PY for oGLD) and 950 new HHF events were analyzed.
SGLT-2i was associated with significant lower rates of HHF with/without prior CVD (HR 0.69;95% CI 0.59-0.80) compared with oGLD (HR 0.55, 95% CI 0.34-0.88).
Similarly, death and composite endpoint was significantly lower for SGLT-2i when compared to oGLD, irrespective of heart failure or CVD.
SGLT-2i was associated with significant reduction in HHF and death vs oGLD in both with/without prior CVD or heart failure patients, which shows the beneficial effect of SGLT-2i over broad range of patient population with T2DM.
This study used clinical practice data from 2012-2016 and compared HHF and death in patient with/without prior CVD or heart failure in new users of SGLT-2i vs other glucose lowering drugs (oGLD).
HHF and deaths were collected via medical records, medical claims, electronic health and death records, and national register; Hazard ratio (HR) for HHF, death and the composite endpoint (HHF or death) was calculated as average.
Overall, 306,156 patients with >150,000 person year(PY) 100,947 PY for SGLT-2i; 89,208 PY for oGLD) and 950 new HHF events were analyzed.
SGLT-2i was associated with significant lower rates of HHF with/without prior CVD (HR 0.69;95% CI 0.59-0.80) compared with oGLD (HR 0.55, 95% CI 0.34-0.88).
Similarly, death and composite endpoint was significantly lower for SGLT-2i when compared to oGLD, irrespective of heart failure or CVD.
SGLT-2i was associated with significant reduction in HHF and death vs oGLD in both with/without prior CVD or heart failure patients, which shows the beneficial effect of SGLT-2i over broad range of patient population with T2DM.
